Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_4
1
20%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Other(2)

Detailed Status

Completed3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 41 (25.0%)

Trials by Status

unknown240%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

NCT03637556
unknown

Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03659084
completedphase_4

Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

NCT00452660
completedphase_1

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis

NCT01278056
unknownphase_2

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

NCT01284946

Clinical Trials (5)

Showing 5 of 5 trials
NCT03637556Phase 2

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Completed
NCT03659084

Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

Unknown
NCT00452660Phase 4

Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

Completed
NCT01278056Phase 1

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis

Completed
NCT01284946Phase 2

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5